Since the development of novel HER2-directed drugs may benefit BC patients with low levels of HER2 expression (IHC 2 + /non-amplified and IHC 1 +) [10], the assay data were further analyzed with respect to their sensitivity and specificity for detecting HER2-low tumors (Fig. 3B). The gene discussed is ERBB2; the disease is breast cancer.